CG Oncology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by CG Oncology, Inc. on June 5, 2025. The record date for the meeting was April 8, 2025, with 76,221,857 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1: Election of Directors
- Arthur Kuan: Elected with 57,636,262.53 shares voted for, 3,625,893.00 withheld, and 8,448,008.47 broker non-votes.
- James J. Mulé: Elected with 34,062,064.00 shares voted for, 27,200,091.53 withheld, and 8,448,008.47 broker non-votes.
- Leonard Post: Elected with 52,459,292.00 shares voted for, 8,802,863.53 withheld, and 8,448,008.47 broker non-votes.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Voting Results: 69,688,802.00 shares voted for, 7,027.00 against, 14,335.00 abstentions, and 0.00 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (76,221,857) against the company's most recent 10-Q or 10-K.
- Note the significant number of broker non-votes (8,448,008.47) on the director election, which may indicate shares held in street name where brokers lacked discretionary voting authority.
- Confirm the tenure of the newly elected directors, who will serve until the 2028 Annual Meeting.
- Verify the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2025.